• The purpose of this study was to generate lymphokine-activated killer cells via alternative pathways using combinations of biologic agents. Immunotherapy with the mouse anti-CD3 analogue combined with low-dose interleukin 2 (IL-2) and tumor necrosis factor α (TNF-α) was tested for in vivo antitumor efficacy against established pulmonary metastases from a variety of mouse tumor-cell lines. Administration of a single dose of anti-CD3 followed by low-dose IL-2 and TNF-α potentiated reduction of metastases compared with higher doses of IL-2 alone or IL-2 plus TNF-α. Treatment with anti-CD3 plus IL-2 plus TNF-α significantly prolonged survival and resulted in 60% of the mice achieving long-term survival compared with no survival using single agents or other combinations. The lymphokine-activated killer and natural killer activities of mouse splenocytes increased following treatment with anti-CD3 plus IL-2 plus TNF-α. These results indicate that the sequential use of anti-CD3, IL-2, and TNF-α for the induction and maintenance of lymphokine-activated killer activity potentiates antitumor activity and provides novel strategies for combination immunotherapy.
(Arch Surg. 1990;125:220-225)
Yang SC, Fry KD, Grimm EA, Roth JA. Successful Combination Immunotherapy for the Generation In Vivo of Antitumor Activity With Anti-CD3, Interleukin 2, and Tumor Necrosis Factor α. Arch Surg. 1990;125(2):220-225. doi:10.1001/archsurg.1990.01410140098016